Circulating osteocalcin, which normally reflects the rate of bone formation, is elevated in uremia. In 18 patients receiving maintenance hemodialysis, serum osteocalcin levels were directly related to the bone formation rate (r = 0.88, P < 0.001), osteoblastic osteoid surface density (r = 0.65, P < 0.01), and osteoclastic resorptive surface density (r = 0.75, P < 0.001). Multiple regression analysis showed that osteocalcin levels remained positively correlated with osteoclastic resorption when the bone formation rate was held constant (P < 0.01). The intimation that the coupling of bone formation and resorption could not explain the relationship between osteocalcin and resorption led us to determine whether fragments of this abundant matrix protein are released by bone resorption and retained in uremia. Sera from dialysis patients with renal osteodystrophy were fractionated by sequential gel filtration and HPLC, and assayed for immunoreactive osteocalcin. When normal serum was analyzed, a single sharp peak was found. In pooled sera from patients with high osteoclastic resorptive surfaces identified by histomorphometry, we found five additional immunoreactive peaks, while three additional peaks were detected in sera from patients with lower osteoclastic surfaces. Bio-Gel P-10 chromatography showed that these multiple peaks were of lower molecular weight than intact osteocalcin. We suggest that the liberation of bone matrix by osteoclasts contributes to the circulating osteocalcin immunoreactivity in uremia.
Introduction
In recent years, several noncollagenous proteins have been implicated in the regulation of skeletal metabolism (1) . One of these proteins, osteocalcin, is synthesized by osteoblasts (2) , comprises 20% of the noncollagenous protein in bone (3) , and contains two to three residues of the calcium-binding amino acid, gamma carboxyglutamic acid (Gla)' (4) . Although Gla residues cause osteocalcin to bind tightly to hydroxyapatite (5) , nanomolar concentrations can be detected in serum by ra-dioimmunoassay (6) . Increased osteocalcin levels are found in the circulation of patients with disorders characterized by increased bone turnover (7) (8) (9) and are normal in nonazotemic patients with nonosseous diseases (10) . Osteocalcin has, therefore, become regarded as specific marker for bone formation (1 1).
Osteocalcin in serum has been thought to be derived exclusively from newly synthesized protein rather than from bone resorption, because within 3 h of exposure to vitamin K-antagonism by warfarin, serum osteocalcin is devoid of Gla, while bone osteocalcin is fully gamma carboxylated (12) . During bone resorption, the protein may be degraded by osteoclasts to nonor weakly immunoreactive fragments. Osteocalcin is cleared rapidly by glomerular filtration (12) and serum levels of immunoreactive osteocalcin are elevated in patients with renal insufficiency (13) . In patients with renal osteodystrophy, the increased osteocalcin levels have been shown to reflect decreased renal clearance and increased bone formation (13, 14) . If, however, fragments of osteocalcin with the appropriate antibody recognition site were released from bone during resorption, these fragments could accumulate and be detected in patients with renal failure. Bone resorption would thus also contribute to the increased serum osteocalcin concentrations found in uremia.
The present study shows that serum osteocalcin levels in dialysis patients are directly related to both bone formation rates and osteoclastic resorptive surfaces and demonstrates the existence of immunoreactive fragments of osteocalcin in uremic sera.
Methods
Subjects. The study group consisted of 18 patients on maintenance dialysis for 4.6±0.8 (SE) years (range, 1 to 13 yr). The mean age was 43.1 yr (range, 23 to 70 years). There were 8 women and 10 men. Renal failure was from hypertension in 11 patients, chronic glomerulonephritis in 5, and interstitial nephritis in 2. Subjects with bone pain, fractures with trivial trauma, radiographic progression of renal osteodystrophy, or hypercalcemia were selected for study from a group of 50 dialysis patients. (18) , osteoclastic resorptive surface (OCL) expressed as the percentage of trabecular surface, osteoclastic resorptive surface density (SVocl) expressed as the decimal fraction of osteoclastic resorptive surface X SV, peritrabecular marrow fibrosis (f) expressed as the percentage of trabecular surface covered by fibrosis tissue, and aluminum surface (Al) expressed as the percentage of total surface that forms a bright red band with the ammonium salt of aurine tricarboxylic acid ( 19) .
Mineral appositional rate (MAR, micrometers per day) was calculated as the mean distance between the midpoints of the double tetracycline labels divided by the interdose duration. All the double-labeled and half the single-labeled trabecular surface were used to determine the fractional extent of active mineralization (LAB). The corrected mineral appositional rate (CMAR, micrometers per day) was calculated as MAR X LAB divided by the osteoid surface X 100. Mean osteoid seam width divided by CMAR gave the corrected mineralization lag time (CMLT, days). Bone formation rate per unit tissue per year (BFR-T, percent per year) was calculated as MAR X LAB X 365 X SV X TBV X l0-4 (20, 21) . All measurements excluded the endosteal borders of the cortices by a distance of two graticule spaces. The slides were examined without knowledge of the serum osteocalcin concentrations.
Reference values were calculated from undecalcified specimens of iliac crest obtained from 33 individuals at autopsy after sudden death (mean age 49.5 yr; range, 20 to 80 yr). There were 15 women and 18 men. The embedded blocks were kindly supplied by Dr. B. L. Riggs. The normal tetracycline data are from four healthy volunteers.
Chromatography. Fasting serum was obtained on the morning of bone biopsy. Osteocalcin was determined by radioimmunoassay as previously described (22) . Serum samples from normal adults or from the dialysis patients were fractionated by gel exclusion chromatography followed by high performance liquid chromatography (HPLC). 1-2 ml of serum from each of five patients with high osteoclastic resorptive surfaces (patients 1, 3, 7, 8, and I1; Table I ) was pooled for one fractionation. 1-2 ml of serum from each of five patients with low osteoclastic resorptive surfaces (patients 13, 14, 16, 17, and 18) was pooled fora separate analysis. Serum from three normal adults was analyzed separately.
5-10 ml of serum were placed on a Sephadex G-100 column (15 X 100 cm) (Pharmacia Fine Chemicals, Uppsala, Sweden), eluted with 3 liters of 50 mM NH2CHO3, and 5-ml fractions were collected. The fractions containing immunoreactive osteocalcin were pooled, lyophilized, and reconstituted in I ml of 50 mM NH2HCO3. The reconstituted fractions were then applied to a Bio-Gel P-10 column (1.5 X 110 cm) (Bio-Rad Laboratories, Richmond, CA) and eluted with the same buffer. The Sephadex fractions with immunoreactive osteocalcin were also characterized by HPLC using a Waters Cl8 MBondapak reverse-phase column (Millipore Corp., Milford, MA). The samples were eluted with a 2-ml/min linear 30-70% solvent B in solvent A gradient [solvent A = 0.1% (vol/vol) tetrafluoroacetic acid (TFA) (Pierce Chemical Co., Rockford, IL); solvent B = 0.1% TFA in 70% acetonitrile (Burdick and Jackson Laboratories Inc., Muskegon, MI)]. Fractions (0.1 ml) were collected and assayed for osteocalcin. Synthetic or enzymatically produced fragments (100-200 ug) were analyzed individually by HPLC. The elution of each fragment was monitored by absorbance at 210 or 276 nm.
Preparation offragments. Fragments corresponding to residues 41-49, 39-49, and 35-49 of bovine osteocalcin were synthesized by the Merrifield solid phase technique (23) with a Beckman automatic peptide synthesizer (Beckman Instruments, Inc., Fullerton, CA). Each fragment was purified by gel filtration with a Bio-Gel P-2 column. Purity was confirmed by HPLC and amino acid analysis.
Fragments 1-19, 1-40, 20-43, and 45-49 from bovine osteocalcin were prepared by trypsin or carboxypeptidase Y digestion as previously described (24) . Individual peptides from the enzymatic digests were separated by HPLC and identified by amino acid analysis.
The immunoreactivity of each fragment in the standard radioimmunoassay was determined by assaying 0.3 ng/ml to 3.0 ,g/ml of peptide serially diluted in 
Results
Histomorphometry. The osteocalcin levels and histomorphometric data are shown in Table I . There was the expected wide spectrum of bone turnover typical of renal osteodystrophy (26) . Patients 1-5 showed accelerated bone formation rates when compared with normal subjects (>6.60%/yr), while patients 13-18 had subnormal rates (<0.70%/yr). Accelerated bone turnover was characterized by an augmented trabecular bone volume with an abundance of woven bone. Relative osteoid volume and osteoid surface, osteoblastic osteoid, osteoclastic resorptive, and fibrosis-lined surfaces were prominent. Aluminum-stained trabecular surface and aluminum-stained cement lines were found in some ofthe patients with accelerated bone formation. In these patients, double tetracycline labels were sometimes noted at sites that stained positively for aluminum (19) . Decreased bone turnover was characterized by extraordinarily increased osteoid volume, surface, and seam thickness. Lamellar bone was prevalent. When compared with the biopsies from patients with accelerated bone turnover, there was a relative paucity ofosteoblastic osteoid and osteoclastic resorptive surfaces, although osteoblastic and osteoclastic surfaces were often greater than normal. Aluminum stained trabecular surface was detected in all the patients with reduced bone turnover.
Serum osteocalcin. The osteocalcin levels ranged from 12 to 317 ng/ml, values 1.7 to 45 times the normal mean (7.1±2.5 SD). Serum osteocalcin levels were directly related to the bone formation rate per unit volume of tissue per year (r = 0.88, P < 0.001) (Fig. 1) . The relationship between osteocalcin levels and the bone formation rate was still significant when patients with bone formation rate values of zero were deleted (r = 0.86, P< 0.001). The serum osteocalcin levels were also directly related to the corrected mineral appositional rate (r = 0.58, P < 0.01), to the osteoblastic osteoid surface density (r = 0.65, P < 0.01), and to the osteoclastic resorptive surface density (r = 0.75, P <0.001). Osteoblastic osteoid and osteoclastic resorptive surface were positively correlated (r = 0.49, P < 0.05) and the osteoblastic osteoid and osteoclastic resorptive surface density measurements directly related to the bone formation rate (r = 0.73, P < 0.001 and r = 0.68, P < 0.01, respectively).
Because bone formation and resorption are coupled in renal osteodystrophy (14, 26) , the positive correlation between serum osteocalcin and osteoclastic resorptive surface was expected. We used stepwise multiple regression analysis to determine if there was a portion of the relationship between osteocalcin levels and bone resorption that was independent of coupling. When bone formation rates were held constant, the positive relationship between osteocalcin levels and osteoclastic resorption persisted (P <0.01). A majority ofthe variation in osteocalcin concentrations (78%) was accounted for by changes in the bone formation rate with an additional 4.0% due to changes in osteoclastic resorptive surface density.
Antibody specificity. Fragments 1-19, 20-43, and 45-49 derived from tryptic digestion, 1-40 from carboxypeptidase Y digestion, and synthetic fragment 41-49 were not immunoreactive. The antiserum could detect the 15 residue (35-49) (Fig. 2, curve B) and the 11 residue (39-49) (Fig. 2, curve C fragments but only at high concentrations (1,500 and 10,000 times the intact molecule, respectively). Additive immunoreactivity was found when increasing concentrations of fragment 35-49 were combined with 1 ng/ml ofpurified bovine osteocalcin (Fig. 2, curve E) . Chromatography. Immunoreactive osteocalcin from healthy adults or dialysis patients eluted from Sephadex G-100 in a single peak. Subsequent HPLC of the G-100 peak obtained from the normal adults eluted as a single sharp peak in three separate experiments (Fig. 3) . Bio-Gel P-10 chromatography of either of the serum pools from the dialysis patients resulted in a sharp immunoreactive peak eluting in the position ofintact osteocalcin and a second broad peak with apparent molecular mass of 3,500 to 5,500 D (Fig. 4, solid circles) . Multiple immunoreactive forms of osteocalcin were detected when these samples were separated by HPLC (Fig. 5) . In addition to a peak that coeluted with intact osteocalcin and one that eluted afterwards, two peaks were found that eluted before intact osteocalcin when serum from patients with low osteoclastic resorptive surfaces was chromatographed and four peaks were detected before the intact peptide in the serum from patients with high osteoclastic resorptive surfaces. All the synthetic and enzymatically prepared fragments eluted before intact osteocalcin.
Discussion
In nonazotemic women with osteoporosis, serum osteocalcin levels correlate with bone formation rates but not with bone resorption (1 1). Our studies demonstrate that in dialysis patients, osteocalcin measurements in serum are related to both the rate of bone formation (Fig. 1 ) and the extent of osteoclastic bone resorption. The conclusion that the relationship between osteocalcin levels and bone resorption is independent ofthe coupling of bone formation and resorption, is supported by the chromatographic elution profile (Fig. 5) . Multiple immunoreactive forms of osteocalcin are present in uremic serum. The second broad peak ofimmunoreactive osteocalcin eluting from Bio-Gel P-IO (Fig. 4) indicates that these multiple forms are smaller than the intact molecule. Although these fragments are rapidly cleared from serum and cannot be detected when renal function is normal (Fig. 3) , the fragments accumulate in renal osteodystrophy and contribute to the circulating immunoreactivity in uremia (Fig. 5) . 100 to 1000 ng/ml; E = 50 to 1000 ng/ml of the 35-49 fragment added to 1 ng/ml of purified intact osteocalcin showing that the apparent reactivities are additive. is that during the accelerated bone formation of renal osteodystrophy, the synthesis of osteocalcin may be altered. Third, in uremia, circulating osteocalcin may become nonenzymatically carbamylated by the condensation of urea-derived cyanate with amino groups. Similar carbamylation occurs with hemoglobin and is proportional to the blood urea concentration (27) . Gundberg and Gallop (28) have shown that in bone osteocalcin can become nonenzymatically glycosylated and it is possible that osteocalcin can also become carbamylated. Furthermore, the single peak that eluted following intact osteocalcin in our HPLC system (Fig. 5) has the same retention time as synthetic carbamylated osteocalcin (data not shown).
Our concept of the metabolism of osteocalcin is illustrated in Fig. 6 . Osteocalcin is synthesized in the osteoblast (2) and is subject to stimulation by 1,25(OH)2D (29) . Gla appears in osteocalcin as a result of posttranslational vitamin K-dependent carboxylation of the glutamyl residues (2). Binding to calcium ions induces a conformational change in the molecule, which anchors osteocalcin to hydroxyapatite (5), so that most of the osteocalcin synthesized by osteoblasts remains in bone. Some osteocalcin escapes the bone and can be detected in the circulation by radioimmunoassay (6) . When bone is resorbed, osteoclasts liberate osteocalcin fragments. With normal renal function, osteocalcin and these fragments are rapidly cleared by the kidney and contribute to the urine free Gla. In renal failure, these fragments accumulate and are detectable. The molecular heterogeneity of circulating osteocalcin is reminiscent of that of immunoreactive parathyroid hormone in uremic patients (30) . The results of the present study suggest that differences in reports from various laboratories may reflect the sensitivity of the individual antibody for the circulating fragments of osteocalcin and that the radioimmunoassay is only valid as an index ofbone formation in the absence of renal insufficiency. With appropriate monoclonal antibodies, it could be possible in the future to distinguish intact from specific fragments of osteocalcin and precisely differentiate between bone formation and resorption. 16 18 21 24 
